Page "GlaxoSmithKline" Paragraph 12

* On 26 August 2004, New York State Attorney General Eliot Spitzer's office announced it had settled legal action against GSK.

The settlement required GSK to post a registry which would include much more information about pretrial and clinical drug study results than what the U. S. Food and Drug Administration ( FDA ) and other pharmaceutical companies had thus far been willing to make public.

Attorney General Spitzer hailed the settlement as " transformational in that it will provide doctors and patients access to the clinical testing data necessary to make informed judgments.

" This part of the settlement was the main objective of the New York AG and Rose Firestein, who worked in the office of the AG and initially argued the case should be undertaken.

As for the monetary compensation, both sides finally agreed to $ 2. 5 million.

On 3 August 2004, shortly before the settlement, Senator Charles Grassley, a Republican senator from Iowa, sent a letter to GSK, stating that he was concerned that " some drug companies " may not have provided the FDA with all the information at their disposal.

His letter was spurred by statements earlier in 2008 by Dr. Andrew Mosholder, an FDA official, who had told senators at a 2 February 2004 hearing that " GlaxoSmithKline, in his opinion, was attempting to ' sugar-coat ' the adverse effects of Paxil on children by ' miscoding ' suicidal ideations and / or suicidal behaviour.

" GSK officials never commented on whether there was any connection between Senator Grassley's letter and their decision to pursue a settlement with the New York State attorney general's lawsuit.